Supreme Court Should Pass On Zarxio, Wait For Another Biosimilar Suit, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz's petition challenging biosimilar launch notification requirements isn't urgent, Amgen argues, but if court takes up case, Amgen also wants it to rule on whether patent dance is optional.
You may also be interested in...
Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says
Genentech seeks court order requiring Amgen to provide biosimilar manufacturing info so it can evaluate potential infringement; Supreme Court to hear Zarxio case on April 26.
Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says
Genentech seeks court order requiring Amgen to provide biosimilar manufacturing info so it can evaluate potential infringement; Supreme Court to hear Zarxio case on April 26.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.